1. Home
  2. BEAM vs MYGN Comparison

BEAM vs MYGN Comparison

Compare BEAM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • MYGN
  • Stock Information
  • Founded
  • BEAM 2017
  • MYGN 1991
  • Country
  • BEAM United States
  • MYGN United States
  • Employees
  • BEAM N/A
  • MYGN N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • BEAM Health Care
  • MYGN Health Care
  • Exchange
  • BEAM Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • BEAM 1.9B
  • MYGN 2.0B
  • IPO Year
  • BEAM 2020
  • MYGN 1995
  • Fundamental
  • Price
  • BEAM $28.22
  • MYGN $16.17
  • Analyst Decision
  • BEAM Buy
  • MYGN Buy
  • Analyst Count
  • BEAM 11
  • MYGN 12
  • Target Price
  • BEAM $45.90
  • MYGN $27.64
  • AVG Volume (30 Days)
  • BEAM 1.3M
  • MYGN 864.7K
  • Earning Date
  • BEAM 11-05-2024
  • MYGN 11-07-2024
  • Dividend Yield
  • BEAM N/A
  • MYGN N/A
  • EPS Growth
  • BEAM N/A
  • MYGN N/A
  • EPS
  • BEAM N/A
  • MYGN N/A
  • Revenue
  • BEAM $349,643,000.00
  • MYGN $823,600,000.00
  • Revenue This Year
  • BEAM N/A
  • MYGN $13.85
  • Revenue Next Year
  • BEAM $6.04
  • MYGN $7.73
  • P/E Ratio
  • BEAM N/A
  • MYGN N/A
  • Revenue Growth
  • BEAM 328.73
  • MYGN 12.15
  • 52 Week Low
  • BEAM $20.84
  • MYGN $16.23
  • 52 Week High
  • BEAM $49.50
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 60.98
  • MYGN 18.30
  • Support Level
  • BEAM $21.46
  • MYGN $16.86
  • Resistance Level
  • BEAM $32.29
  • MYGN $19.60
  • Average True Range (ATR)
  • BEAM 1.80
  • MYGN 1.16
  • MACD
  • BEAM 0.74
  • MYGN -0.32
  • Stochastic Oscillator
  • BEAM 61.00
  • MYGN 0.37

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Share on Social Networks: